Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)

@article{Bush2017RecommendationsFT,
  title={Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)},
  author={R. Bush and A. Comerota and M. Meissner and J. Raffetto and S. Hahn and K. Freeman},
  journal={Phlebology},
  year={2017},
  volume={32},
  pages={19 - 3}
}
Scope A systematic review of the clinical literature concerning medical management of chronic venous disease with the venoactive therapy Micronized Purified Flavonoid Fraction was conducted in addition to an investigation of the hemodynamics and mechanism of chronic venous disease. Methods The systematic review of the literature focused on the use of Micronized Purified Flavonoid Fraction (diosmin) which has recently become available in the US, in the management of chronic venous disease. The… Expand

Paper Mentions

Interventional Clinical Trial
In this randomized controlled trial (RCT), the investigators will determine whether a 6-month course of oral Micronized Purified Flavonoid Fraction (MPFF 1000 mg daily), compared with… Expand
ConditionsPost-Thrombotic Syndrome
InterventionDrug
Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
  • S. Kakkos, A. Nicolaides
  • Medicine
  • International angiology : a journal of the International Union of Angiology
  • 2018
TLDR
Micronized purified flavonoid fraction significantly improved nine defined leg symptoms, including pain, heaviness, feeling of swelling, cramps, paresthesia, burning sensation, and pruritus, but also functional discomfort compared with placebo, leg redness, skin changes and QoL. Expand
[Efficacy of micronized purified flavonoid fraction in treatment of chronic venous oedema].
TLDR
Positive dynamics of venous-specific symptoms appeared to be accompanied by significant improvement of all dimensions of quality of life according to the CIVIQ-14 scale, and it appears absolutely logical to predominantly use the micronized purified flavonoid fraction in real clinical practice in patients with the CEAP C3 clinical class. Expand
Clinical Efficacy of Conservative Treatment with Micronized Purified Flavonoid Fraction in Female Patients with Pelvic Congestion Syndrome
Pelvic congestion syndrome (PCS) may be effectively managed with conservative treatment in certain patients. Treatment with venoactive drugs is common, but supportive data are limited. This studyExpand
Effectiveness and safety of micronized purified flavonoid fraction for the treatment of concomitant varicose veins of the pelvis and lower extremities
TLDR
Phlebotropic treatment with MPFF is an effective and safe method of conservative therapy in patients with concomitant VVP and VVLE and reduces blood stasis in the pelvic venous plexuses. Expand
Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management
TLDR
The aim of the present review is to collect the current knowledge of CVD, including its epidemiology, etiology, and risk factors, but emphasizing the pathophysiology and medical care of patients, including clinical manifestations, diagnosis, and treatments. Expand
Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy
TLDR
This work aims to review the pathophysiological mechanisms of CVD and their implications regarding currently available venoactive drug therapies, as well as potential targets and strategies for therapeutic intervention. Expand
Evaluation and Management of Chronic Venous Disease Using the Foundation of CEAP
TLDR
A thorough clinical assessment, appropriate duplex ultrasound imaging, and use of advanced imaging when needed will allow clinicians to optimize therapy for patients with chronic venous disease based on the etiology, anatomy involved, and the pathophysiology. Expand
Venous Stasis Ulcers: an Update on Diagnosis and Management
TLDR
The gold standard for the prevention and treatment of VLU is compression therapy and should be utilized with the TIME strategy which contributes to the stimulation of natural healing mechanisms and includes the following: Tissue debridement, infection and inflammation control, Moisture balance, and Epidermization stimulation. Expand
Management and evaluation of treatment adherence and effectiveness in chronic venous disorders: results of the international study VEIN Act Program
TLDR
Conservative treatments were beneficial across the spectrum of CVD, highlighting the importance of identifying patients early in the disease course. Expand
The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence
TLDR
International guidelines are available to help physicians consider CVD treatment options and refer patients when warranted to decrease this treatment gap and prevent unnecessary disease progression. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 53 REFERENCES
Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study.
TLDR
Micronised purified flavonoidic fraction treatment for 60 days seems to decrease the levels of some plasma markers of endothelial activation, which could ameliorate the dermatological effects of chronic venous disease. Expand
A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
TLDR
In this study, MPFF did not change the symptoms of CVD, except night cramps, and a secondary finding was reduced reflux times in patients with oedema, although no ultrasonographic or foot-volumetric parameters changed significantly for the whole group. Expand
Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study
TLDR
The RELIEF study provided important information about the epidemiology and clinical manifestations of CVI, with the observation that venous reflux was found to be absent in 57% of patients diagnosed as suffering from CVI belonging to CEAP classes C0 to C4. Expand
Evaluation of a New Venoactive Micronized Flavonoid Fraction (S 5682) in Symptomatic Disturbances of the Venolymphatic Circulation of the Lower Limb: A Double-Blind, Placebo-Controlled Study
TLDR
It is indicated that S 5682 shows early and prolonged efficacy in the treatment of symptomatic disturbances of the venolymphatic system, including chronic venous insufficiency, without significant side-effects. Expand
Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema.
  • F. Allaert
  • Medicine
  • International angiology : a journal of the International Union of Angiology
  • 2012
TLDR
This meta-analysis confirms the validity of the grade A assigned to MPFF in the management of symptoms and edema in recent international guidelines. Expand
Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction.
  • P. Coleridge-Smith, C. Lok, A. Ramelet
  • Medicine
  • European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  • 2005
TLDR
It is confirmed that venous ulcer healing is accelerated by MPFF treatment, and MPFF might be a useful adjunct to conventional therapy in large and long standing ulcers. Expand
Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.
TLDR
A 4-month treatment with MPFF significantly reduced leg pain/heaviness and improved QOL when compared to placebo and was well tolerated. Expand
The Beneficial Augmentative Effect of Micronised Purified Flavonoid Fraction (MPFF) on the Healing of Leg Ulcers: An Open, Multicentre, Controlled, Randomised Study
TLDR
It is indicated that MPFF significantly improves the cure rate in patients with chronic venous insufficiency and the cost-effectiveness ratio (cost per healed ulcer) in the MPFF group was €1026.2 compared with €1871.8 in the control group. Expand
Phlebotonics for venous insufficiency.
TLDR
Moderate-quality evidence suggests that phlebotonics reduced oedema in the lower legs compared with placebo, and high- quality evidence suggests no differences in quality of life for calcium dobesilate, as well as some adverse events such as restless legs and trophic disorders. Expand
A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options
TLDR
The major microcirculatory effects that have been shown are the reduction of capillary filtration rate and improvements in levels of transcutaneous partial pressures of oxygen and carbon dioxide (TcPO2 and TcPCO2). Expand
...
1
2
3
4
5
...